Sign in
ALLR Stock Price, Chart, Stats & News
Allarity Therapeutics, Inc.
Save
Allarity Therapeutics, Inc. (ALLR) does not currently pay a dividend.
17.34M
Market cap
–
Current P/E
–
Forward P/E
ALLR chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -73.62% |
ROE | -112.05% |
D/E | 0.12x |
Interest coverage ratio | -84.60x |
ALLR valuation
P/E | – |
P/S | – |
P/B | 1.31x |
P/CF | -1.07x |
P/FCF | -1.14x |
P/OCF | -1.07x |
PEG | -0.01x |
EV multiple | -2.17x |
About
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer.
Similar securities
Based on sector and market capitalization
Report issue